Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Common Equity (2021 - 2025)

Historic Common Equity for HeartSciences (HSCS) over the last 5 years, with Q4 2025 value amounting to $4.2 million.

  • HeartSciences' Common Equity rose 412.65% to $4.2 million in Q4 2025 from the same period last year, while for Oct 2025 it was $4.2 million, marking a year-over-year increase of 412.65%. This contributed to the annual value of $205171.0 for FY2025, which is 9719.61% down from last year.
  • Per HeartSciences' latest filing, its Common Equity stood at $4.2 million for Q4 2025, which was up 412.65% from $3.1 million recorded in Q3 2025.
  • HeartSciences' 5-year Common Equity high stood at $8.6 million for Q1 2024, and its period low was -$6.1 million during Q2 2022.
  • Its 5-year average for Common Equity is $1.8 million, with a median of $1.4 million in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 25237.08% in 2023, then skyrocketed by 344758.99% in 2024.
  • Quarter analysis of 5 years shows HeartSciences' Common Equity stood at -$1.9 million in 2021, then soared by 156.7% to $1.1 million in 2022, then tumbled by 252.37% to -$1.6 million in 2023, then surged by 343.48% to $4.0 million in 2024, then increased by 4.13% to $4.2 million in 2025.
  • Its Common Equity stands at $4.2 million for Q4 2025, versus $3.1 million for Q3 2025 and $205171.0 for Q2 2025.